DelveInsight’s latest report on "Janus Kinase (JAK) Inhibitor Pipeline Insight" outlays comprehensive insights of present clinical development scenario and growth prospects across the Janus Kinase (JAK) Inhibitor market.
The report covers an in-depth analysis of the commercial and clinical activities of the Janus Kinase (JAK) Inhibitor pipeline products from the pre-clinical developmental phase to the marketed phase. It also provides a detailed description of the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing mergers and acquisition, and other product-related details.
Janus Kinase (JAK) Inhibitor Pipeline Insights: An Overview
Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses.
The family of cytokines that signal via JAKs includes many interleukins, interferons, colony-stimulating factors, and hormone-like cytokines (such as erythropoietin). The receptors for these cytokines signal via various combinations of four JAKs (JAK1, JAK2, JAK3, and TYK2).
Topical JAK inhibitors provide an attractive treatment option for patients with psoriasis, atopic dermatitis, alopecia areata, and vitiligo. A surprise in the field is that targeting JAK in the treatment of skin-related illnesses such as vitiligo and alopecia areata is an inspiring research area, as JAK inhibitors led to a dramatic improvement in symptoms and signs.
Janus Kinase (JAK) Inhibitor Market
Globally, several key companies are working in the Janus Kinase (JAK) Inhibitor segment. As per DelveInsight, the worldwide Janus kinase (JAK) inhibitors market is expected to grow by 2030 at a significant CAGR. After the approval of JAK inhibitors for autoimmune disorders, the proven high efficacy of these drugs would drive the market.
Key Strengths of the Janus Kinase (JAK) Inhibitor Pipeline Report
- Current options for Janus Kinase (JAK) Inhibitor treatment
- Therapies developed by the leading industry players
- Emerging therapies in various stages of development
- Ongoing clinical studies and the safety and efficacy of ther therapies
- Types of therapies (i.e monotherapy and in combination)
- Key companies working in the Janus Kinase (JAK) Inhibitor segment
- Dormant and discontinued products
- Key collaborations, mergers, and acquisitions, and Unmet need
- Recent novel therapies, targets, mechanisms of action, and emerging technologies
Some of the key companies in the Janus Kinase (JAK) Inhibitor Market include:
- Sierra Oncology
- Pfizer
- Theravance Biopharma
- Dizal Pharmaceutical
- Aclaris Therapeutics
- Celon Pharma
- Theravance Biopharma
And many others
Janus Kinase (JAK) Inhibitor Therapies covered in the report include:
- TD-5202
- CPL409116
- ATI-2138
- DZD4205
- TD-8236
- PF-06651600
- Momelotinib
And many more
Scope of the Report
- Janus Kinase (JAK) Inhibitor report covers the therapeutics pipeline activity by development stage, product type, route of administration, molecule type, and MOA.
- The report also covers the Janus Kinase (JAK) Inhibitor therapeutic products including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details
- A detailed study of the research and development progress, trial details, dormant and discontinued pipeline projects, are also analyzed in the report.
For more detailed information, visit: Janus Kinase (JAK) Inhibitor Pipeline Insights and Key Companies